Chinook Therapeutics (KDNY) Income Statement (2020 - 2023)
Income Statement report data from Dec 31, 2020 to Jun 30, 2023 for Chinook Therapeutics (KDNY).
Reported currency: USD
| Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||
Total Revenue | 1.01M (-44.81%) | 1.83M (+258.82%) | 510K (-79.60%) | 2.50M (+495.24%) | 420K (-84.44%) | 2.70M (-94.73%) | 51M | - | 30K (-91.43%) | 350K | -22.48M |
Gross Profit | 1.01M (-44.81%) | 1.83M (+258.82%) | 510K (-79.60%) | 2.50M (+495.24%) | 420K (-84.44%) | 2.70M (-94.73%) | 51M | - | 30K (-91.43%) | 350K | -22.48M |
Operating Expenses | |||||||||||
Research And Development | 58M (+13.80%) | 51M (+18.46%) | 43M (+2.31%) | 42M (+39.84%) | 30M (+14.36%) | 26M (+5.29%) | 25M (+5.77%) | 24M (+3.42%) | 23M (-11.32%) | 26M (+17.94%) | 22M |
Selling General And Administrative | 13M (+14.56%) | 11M (+16.68%) | 9.77M (-2.50%) | 10M (+15.97%) | 8.64M (+9.78%) | 7.87M (+1.68%) | 7.74M (+12.99%) | 6.85M (-11.84%) | 7.77M (-18.55%) | 9.54M (-13.43%) | 11M |
Operating Expenses | 74M (+16.41%) | 63M (+4.68%) | 60M (+0.40%) | 60M (+62.21%) | 37M (+10.71%) | 34M (-13.75%) | 39M (+25.28%) | 31M (-38.63%) | 51M (+34.75%) | 38M (+7.94%) | 35M |
Depreciation And Amortization | 430K (0.00%) | 430K (0.00%) | 430K (0.00%) | 430K (0.00%) | 430K (0.00%) | 430K (+2.38%) | 420K (0.00%) | 420K (0.00%) | 420K (0.00%) | 420K (0.00%) | 420K |
Operating Income | |||||||||||
Operating Income | -72.63M (+18.25%) | -61.42M (+2.52%) | -59.91M (+3.87%) | -57.68M (+57.25%) | -36.68M (+19.05%) | -30.81M | 12M | -31.01M (-38.59%) | -50.50M (+35.94%) | -37.15M (+9.52%) | -33.92M |
EBITDA | -70.71M (+17.63%) | -60.11M (+2.51%) | -58.64M (+1.66%) | -57.68M (+62.85%) | -35.42M (+19.99%) | -29.52M | 14M | -29.89M (-39.41%) | -49.33M (+37.33%) | -35.92M (+9.68%) | -32.75M |
Other Income / Expenses | |||||||||||
Interest Income | 3.67M (+18.39%) | 3.10M | - | - | 770K | -90.00K | - | - | - | - | -1.20M |
Net Interest Income | 3.67M (+18.39%) | 3.10M | - | - | 770K | -90.00K | - | - | - | - | -1.20M |
Other Non Operating Income | - | - | - | 1.69M | - | - | - | -70.00K | 7.19M | -70.00K (-99.62%) | -18.30M |
Net Income | |||||||||||
Income Before Tax | -68.96M (+18.24%) | -58.32M (+1.50%) | -57.46M (+2.63%) | -55.99M (+55.87%) | -35.92M (+16.21%) | -30.91M | 12M | -31.07M (-28.26%) | -43.31M (+16.36%) | -37.22M (-28.31%) | -51.92M |
Income Tax Expense | - | - | 4.34M | - | - | - | 3.30M | -460.00K (-37.84%) | -740.00K | - | -2.00M |
Net Income From Continuing Operations | -66.94M (+11.23%) | -60.18M (-3.79%) | -62.55M (+11.74%) | -55.98M (+48.69%) | -37.65M (+18.84%) | -31.68M | 7.55M | -30.70M (-27.88%) | -42.57M (+14.37%) | -37.22M (-25.43%) | -49.91M |
Net Income | -66.94M (+11.23%) | -60.18M (-3.79%) | -62.55M (+11.74%) | -55.98M (+48.69%) | -37.65M (+18.84%) | -31.68M | 7.55M | -30.70M (-27.88%) | -42.57M (+14.37%) | -37.22M (-25.43%) | -49.91M |